---
{"dg-publish":true,"permalink":"/Reference notes/Readwise/Tweets/Tranexamic Acid - It's.../"}
---

# ğŸš© Tranexamic AcidÂ - It's...

![rw-book-cover](https://pbs.twimg.com/profile_images/378800000356963215/7b87d5c360583e770c087682f0a6e13e.png)

## Metadata
- Author: [[@CritCareReviews on Twitter\|@CritCareReviews on Twitter]]
- Full Title: ğŸš© Tranexamic AcidÂ - It's...
- Category: #tweets
- URL: https://twitter.com/CritCareReviews/status/1638986108561408000

## Highlights
- ğŸš© Tranexamic AcidÂ - it's complicated....
  â¡ï¸It's widely used for treatment & prevention of haemorrhage
  â¡ï¸It's in the WHO's List of Essential Medicines & recommended in the European Traumatic Haemorrhage guideline (2023)
  â¡ï¸But is it as efficacious as we think?
  ğŸ§µ 1/17 
  ![](https://pbs.twimg.com/media/Fr7ZLdtX0BEIgkv.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986108561408000))
- ğŸš© History
  â¡ï¸Drs. Utako & Shosuke Okamoto invented TXA in 1962
  â¡ï¸They identified that the amino acid lysine inhibited the degradation of plasmin, a profibrinolytic enzyme
  â¡ï¸Lysine was modified to first produce Epsilon- Amino-Caproic Acid and later TXA, x 27 more potent
  2/17 
  ![](https://pbs.twimg.com/media/Fr7ZMdMXgAAF8ff.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986124818530304))
- ğŸš© Pharmacology
  â¡ï¸TXA is a molecular analog of lysine 
  â¡ï¸It inhibits fibrinolysis by preventing the binding of plasminogen to fibrin
  â¡ï¸This inhibits plasmin formation & displaces plasminogen from the fibrin surface
  â¡ï¸It also has effects on the immune system & inflammation
  3/17 
  ![](https://pbs.twimg.com/media/Fr7ZM9YX0AAKFbX.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986133844692993))
- ğŸš©Landmark Trials
  A number of major TXA trials for acute bleeding have been published over the past 13 years, with varying results
  â¡ï¸CRASH-2 & STAAMP - traumatic haemorrrhage
  â¡ï¸WOMAN - Post partum haemorrhage
  â¡ï¸HALT-IT - Upper GI bleeding
  â¡ï¸CRASH-3 & Rowell - TBI
  4/17 
  ![](https://pbs.twimg.com/media/Fr7ZNi3X0AIaZe1.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986143931965440))
- ğŸš©CRASH-2
  â¡ï¸The landmark CRASH-2 trial was published in 2010 
  â¡ï¸20,211 adult trauma patients with, or at risk of, significant bleeding were randomised to TXA or placebo
  â¡ï¸all-cause mortality â¬‡ï¸ by 1.5% (14.5% vs 16%)
  â¡ï¸risk of death from bleeding â¬‡ï¸ by 15% (4.9% vs 5.7%)
  5/17 
  ![](https://pbs.twimg.com/media/Fr7ZOBIX0AwTgUM.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986151834062850))
- ğŸš©STAAMP
  â¡ï¸STAAMP was published in 2020
  â¡ï¸903 adults at risk for hemorrhage after trauma
  â¡ï¸prehospital administration of tranexamic acid or placebo
  â¡ï¸30 day mortality 8.1% vs 9.9% (difference, â€“1.8%; 95% CI, â€“5.6% to 1.9%; Pâ€‰=â€‰0.17)
  6/17 
  ![](https://pbs.twimg.com/media/Fr7ZOf_WcAANufV.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986161057325056))
- ğŸš©Rowell Trial
  â¡ï¸Published 2020
  â¡ï¸1063 patients with moderate - severe TBI
  â¡ï¸20 hospitals, 39 EMS in 2 countries
  â¡ï¸primary outcome - favorable neurologic function at 6 months (GOSE >4) 
  â¡ï¸results were similar: 65% vs 62% (Pâ€‰=â€‰0.84)
  7/17 
  ![](https://pbs.twimg.com/media/Fr7ZPHWX0Age-T8.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986170620329984))
- ğŸš©CRASH-3
  â¡ï¸Published 2019
  â¡ï¸12737 TBI patients
  â¡ï¸175 hospitals in 29 countries
  â¡ï¸primary outcome was head injury-related death in hospital within 28 days of injury in patients treated within 3 h of injury
  â¡ï¸results were similar: 18.5% v 19.8% (RR 0.94; 95% CI, 0.86â€“1.02)
  8/17 
  ![](https://pbs.twimg.com/media/Fr7ZPkRWcAEp0Nz.png) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986178543382528))
- ğŸš©WOMAN
  â¡ï¸Published 2017
  â¡ï¸20,060 women with post-partum haemorrhage
  â¡ï¸193 hospitals in 21 countries
  â¡ï¸primary outcome - composite of death or hysterectomy < 42 days
  â¡ï¸results were similar: 5.3% vs 5Â·5%; P=0.65
  â¡ï¸death from bleeding was â¬‡ï¸ with TXA (1.5% vs 1.9%; P=0.045)
  9/17 
  ![](https://pbs.twimg.com/media/Fr7ZQBKX0AAQUH5.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986185984053250))
- ğŸš©HALT-IT
  â¡ï¸Published 2020
  â¡ï¸12,009 pts with acute GI bleed
  â¡ï¸164 hospitals in 15 countries
  â¡ï¸primary outcome - death due to bleeding within 5 days
  â¡ï¸results were similar: 4% vs 4% (RR 0Â·99, 95% CI 0Â·82â€“1Â·18)
  â¡ï¸TXA caused â¬†ï¸ venous thromboembolic events (0.8% vs 0.4%)
  10/17 
  ![](https://pbs.twimg.com/media/Fr7ZQc5X0A8v0-c.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986193277943808))
- ğŸš©But, but, but...
  â¡ï¸Following CRASH-2, TXA has been widely used and investigated in various haemorrhagic conditions
  â¡ï¸Despite being a large international RCT, CRASH-2 raised many questions & divided opinion
  11/17 
  ![](https://pbs.twimg.com/media/Fr7ZQ_4WcAAEgX5.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986202627076096))
- ğŸš©Mechanism of Effect
  â¡ï¸The mechanism of effect in CRASH-2 wasn't clear
  â¡ï¸Rates of blood transfusion were similar
  â¡ï¸Little data was available to explore other potential effects of TXA as the responsible mediator
  12/17 
  ![](https://pbs.twimg.com/media/Fr7ZRZjX0AIqpVO.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986209279229952))
- ğŸš©Timing Issue
  â¡ï¸There was an apparent differential response according to the timing of TXA administration
  â¡ï¸< 1 hour - mortality 5.3% vs 7.7%
  â¡ï¸1-3 hours - mortality 4.8% vs 6.1%
  â¡ï¸> 3 hours - mortality 4.4% vs 3.1%
  13/17 
  ![](https://pbs.twimg.com/media/Fr7ZRw-XoAc1x8r.png) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986215864270848))
- ğŸš©Generalisability 
  â¡ï¸98% of patients came from outside high income countries
  â¡ï¸would TXA still be beneficial within a more comprehensive trauma system?
  â¡ï¸would more advanced treatments dilute its effects?
  â¡ï¸blood products / interventional radiology / REBOA ğŸ˜‰
  14/17 
  ![](https://pbs.twimg.com/media/Fr7ZSc8WcAAkpFd.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986228120059905))
- ğŸš©Specificity
  â¡ï¸The inclusion criteria have limited utility in recognising haemorrhage
  â¡ï¸HR > 110/min & SBP < 90 mmHg
  â¡ï¸neither do they identify acute traumatic coagulopathy (ATC) in pts who are more likely to benefit 
  â¡ï¸including non ATC patients may â¬†ï¸ thromboses risk
  15/17 
  ![](https://pbs.twimg.com/media/Fr7ZS_UX0AksShr.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986237750177792))
- ğŸš©PATCH Trial
  â¡ï¸Enter the PATCH Trial
  â¡ï¸Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage
  â¡ï¸TXA (starting prehospital) vs placebo in 1316 patients with severe trauma at risk of ATC
  â¡ï¸Australia / NZ / Germany
  â¡ï¸Primary Outcome GOSE at 6â€‰months
  16/17 
  ![](https://pbs.twimg.com/media/Fr7ZTdyWwAIA02P.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986245903912966))
- ğŸš© Is TXA beneficial in more resourced healthcare systems?
  Join us in @TitanicBelfast to hear @RussellGruen present the results of the @PATCHTrial
  https://t.co/RD6WAgBYL3
  @HawkmoonHEMS
  17/17 
  ![](https://pbs.twimg.com/media/Fr7ZUKJWAAA9ncB.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986258063167488))
- @TitanicBelfast @RussellGruen @PATCHTrial @HawkmoonHEMS References 
  ![](https://pbs.twimg.com/media/Fr7ZUwHX0BMak0_.jpg) ([View Tweet](https://twitter.com/CritCareReviews/status/1638986267915603968))
